Wordt geladen...
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial
BACKGROUND: Vinorelbine constitutes effective chemotherapy for metastatic breast cancer (MBC) and acts synergistically with trastuzumab in HER-2/neu positive disease. The present study was set out to evaluate the efficacy and safety of vinorelbine when combined with lapatinib, an anti-HER2 tyrosine-...
Bewaard in:
Gepubliceerd in: | BMC Cancer |
---|---|
Hoofdauteurs: | , , , , , , , , , |
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
BioMed Central
2016
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4758093/ https://ncbi.nlm.nih.gov/pubmed/26887956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2171-y |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|